Journal
CURRENT OPINION IN PHARMACOLOGY
Volume 25, Issue -, Pages 36-44Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.coph.2015.09.013
Keywords
-
Categories
Funding
- Portuguese Foundation for Science and Technology (FCT, GABBA program) [SFRH/BD/52036/2012]
- EU-FP7 METACARDIS [HEALTH-F4-2012-305312]
- Nestle [RDLS015375]
- Malaysian Government Agency (MARA) [330400647241]
- Metabometrix Ltd.
- EU (Metacardis) [HEALTH-F4-2012-305312, 291840]
- MRC [MR/M501797/1]
- Fundação para a Ciência e a Tecnologia [SFRH/BD/52036/2012] Funding Source: FCT
- MRC [MR/M501797/1] Funding Source: UKRI
- Medical Research Council [MR/M501797/1] Funding Source: researchfish
Ask authors/readers for more resources
Consisting of trillions of non-pathogenic bacteria living in a symbiotic relationship with their mammalian host, the gut microbiota has emerged in the past decades as one of the key drivers for cardiometabolic diseases (CMD). By degrading dietary substrates, the gut microbiota produces several metabolites that bind human pharmacological targets, impact subsequent signalling networks and in fine modulate host's metabolism. In this review, we revisit the pharmacological relevance of four classes of gut microbial metabolites in CMD: short-chain fatty acids (SCFA), bile acids, methylamines and indoles. Unravelling the signalling mechanisms of the microbial mammalian metabolic axis adds one more layer of complexity to the physiopathology of CMD and opens new avenues for the development of microbiota-based pharmacological therapies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available